Browse the corpus

REFERENCES Agnelli G, Buller HR, Cohen A, et al, “Apixaban for Extended Treatment of Venous Thromboembolism,” N Engl J Med , 2013, 368(8):699-708. [PubMed 23216615 ] Alexander JH, Lopes RD, James S, et al, “Apixaban With Antiplatelet Therapy After Acute Coronary Syndrome,” N Engl J Med , 2011, 365(8):699-708. [PubMed 21780946 ] APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, et al, “Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial,” Circulation , 2009, 119(22):2877-85. [PubMed 19470889 ] Bates SM, Greer IA, Middeldorp S, et al. “VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest , 2012, 141(2 Suppl):e691-736. [PubMed 22315276 ] Connolly SJ, Eikelboom J, Joyner C, et al, “Apixaban in Patients With Atrial Fibrillation,” N Engl J Med , 2011, 364(9):806-17. [PubMed 21309657 ] Escolar G, Arellano-Rodrigo E, Reverter JC, et al, “Reversal of Apixaban Induced Alterations of Hemostasis by Different Coagulation Factor Concentrates: Studies in vitro With Circulating Human Blood,” Circulation , 2012, 126(4):520-1. Available at file://circ.ahajournals.org/content/early/2012/06/20/CIR.0b013e3182611cc2 [PubMed 22718802 ] Frost C, Wang J, Nepal S, et al, "Apixaban, an Oral, Direct Factor Xa Inhibitor: Single-Dose Safety, Pharmacokinetics, Pharmacodynamics and Food Effect in Healthy Subjects," Br J Clin Pharmacol , 2012 [epub ahead of print]. [PubMed 22759198 ] Furie KL, Goldstein LB, Albers GW, et al, “Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals from the American Heart Association/American Stroke Association,” Stroke , 2012, 43(12):3442-53. [PubMed 22858728 ] Goldhaber SZ, Leizorovicz A, Kakkar AK, et al, “Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients,” N Engl J Med , 2011, 365(23):2167-77. [PubMed 22077144 ] Granger CB, Alexander JH, McMurray JJ, et al, "Apixaban versus Warfarin in Patients With Atrial Fibrillation," N Engl J Med , 2011, 365(11):981-92. [PubMed 21870978 ]

Goldhaber SZ, Leizorovicz A, Kakkar AK, et al, “Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients,” N Engl J Med , 2011, 365(23):2167-77. [PubMed 22077144 ] Granger CB, Alexander JH, McMurray JJ, et al, "Apixaban versus Warfarin in Patients With Atrial Fibrillation," N Engl J Med , 2011, 365(11):981-92. [PubMed 21870978 ] Hohnloser SH, Hijazi Z, Thomas L, et al, “Efficacy of Apixaban When Compared With Warfarin in Relation to Renal Function in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial,” Eur Heart J , 2012, 33(22):2821-30. [PubMed 22933567 ] Lassen MR, Gallus A, Raskob GE, et al, “Apixaban versus Enoxaparin for Thromboprophylaxis After Hip Replacement,” N Engl J Med , 2010, 363(26):2487-98. [PubMed 21175312 ] Lassen MR, Raskob GE, Gallus A, et al, “Apixaban or Enoxaparin for Thromboprophylaxis After Knee Replacement,” N Engl J Med , 2009, 361(6):594-604; published erratum appears in N Engl J Med , 2009, 361(18):1814. [PubMed 19657123 ] Lassen MR, Raskob GE, Gallus A, et al, “Apixaban Versus Enoxaparin for Thromboprophylaxis After Knee Replacement (ADVANCE-2): A Randomised Double-Blind Trial,” Lancet , 2010, 375(9717):807-15. [PubMed 20206776 ] Sharma A, Chatterjee S, Lichstein E, et al, “Extended Thromboprophylaxis for Medically Ill Patients With Decreased Mobility: Does It Improve Outcomes?” J Thromb Haemost , 2012, 10(10):2053-60. [PubMed 22863355 ] Topic 85642 Version 20.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.4 - C21.36 Licensed to: Southeast Alabama Med Ctr | Support Tag: [0602-201.211.0.116-ED8D71C93C-S244013.14]